Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 2 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- HC Wainwright & Co.
- Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Capricor Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10/04/2023 | CAPR | Buy Now | Capricor Therapeutics | $3.67 | 989.92% | HC Wainwright & Co. | Joseph Pantginis | $18 → $40 | Maintains | Buy | Get Alert |
| 08/15/2023 | CAPR | Buy Now | Capricor Therapeutics | $3.67 | 390.46% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/16/2023 | CAPR | Buy Now | Capricor Therapeutics | $3.67 | 390.46% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | → Buy | Get Alert |
| 10/26/2022 | CAPR | Buy Now | Capricor Therapeutics | $3.67 | 308.72% | Ladenburg Thalmann | Aydin Huseynov | → $15 | Initiates | → Buy | Get Alert |
| 01/31/2022 | CAPR | Buy Now | Capricor Therapeutics | $3.67 | 390.46% | HC Wainwright & Co. | Joseph Pantginis | $14 → $18 | Maintains | Buy | Get Alert |
| 10/11/2021 | CAPR | Buy Now | Capricor Therapeutics | $3.67 | 281.47% | HC Wainwright & Co. | Joseph Pantginis | — | Maintains | Buy | Get Alert |
What is the target price for Capricor Therapeutics (CAPR)?
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $40.00 expecting CAPR to rise to within 12 months (a possible 989.92% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a maintained with a price target of $18.00 to $40.00. The current price Capricor Therapeutics (CAPR) is trading at is $3.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.